Panel wants FDA to approve Xarelto as preventive stroke therapy

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Panel members said they wanted more alternatives to warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health